|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moul JW and Dawson N: Quality of life
associated with treatment of castration-resistant prostate cancer:
A review of the literature. Cancer Invest. 30:1–12. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamal A, Thao L, Sensintaffar J, Zhang L,
Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.
425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gorska M, Popowska U, Sielicka-Dudzin A,
Kuban-Jankowska A, Sawczuk W, Knap N, Cicero G and Wozniak F:
Geldanamycin and its derivatives as Hsp90 inhibitors. Front Biosci
(Landmark Ed). 17:2269–2277. 2012. View
Article : Google Scholar
|
|
5
|
Ischia J, Saad F and Gleave M: The promise
of heat shock protein inhibitors in the treatment of castration
resistant prostate cancer. Curr Opin Urol. 23:194–200. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weinstein IB and Joe AK: Mechanisms of
disease: Oncogene addiction - a rationale for molecular targeting
in cancer therapy. Nat Clin Pract Oncol. 3:448–457. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
da Rocha Dias S, Friedlos F, Light Y,
Springer C, Workman P and Marais R: Activated B-RAF is an Hsp90
client protein that is targeted by the anticancer drug
17-allylamino-17-demethoxygel-danamycin. Cancer Res.
65:10686–10691. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grbovic OM, Basso AD, Sawai A, Ye Q,
Friedlander P, Solit D and Rosen N: V600E B-Raf requires the Hsp90
chaperone for stability and is degraded in response to Hsp90
inhibitors. Proc Natl Acad Sci USA. 103:57–62. 2006. View Article : Google Scholar :
|
|
9
|
Whitesell L, Bagatell R and Falsey R: The
stress response: Implications for the clinical development of hsp90
inhibitors. Curr Cancer Drug Targets. 3:349–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiosis G and Neckers L: Tumor selectivity
of Hsp90 inhibitors: The explanation remains elusive. ACS Chem
Biol. 1:279–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scheibel T and Buchner J: The Hsp90
complex - a super-chaperone machine as a novel drug target. Biochem
Pharmacol. 56:675–682. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stebbins CE, Russo AA, Schneider C, Rosen
N, Hartl FU and Pavletich NP: Crystal structure of an
Hsp90-geldanamycin complex: Targeting of a protein chaperone by an
antitumor agent. Cell. 89:239–250. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukuyo Y, Hunt CR and Horikoshi N:
Geldanamycin and its anti-cancer activities. Cancer Lett.
290:24–35. 2010. View Article : Google Scholar
|
|
14
|
Li Z, Jia L, Wang J, Wu X, Hao H, Xu H, Wu
Y, Shi G, Lu C and Shen Y: Design, synthesis and biological
evaluation of 17-arylmethylamine-17-demethoxygeldanamycin
derivatives as potent Hsp90 inhibitors. Eur J Med Chem. 85:359–370.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heath EI, Hillman DW, Vaishampayan U,
Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, et
al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in
patients with hormone-refractory metastatic prostate cancer. Clin
Cancer Res. 14:7940–7946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pacey S, Wilson RH, Walton M, Eatock MM,
Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U,
Roels B, et al: A phase I study of the heat shock protein 90
inhibitor alvespimycin (17-DMAG) given intravenously to patients
with advanced solid tumors. Clin Cancer Res. 17:1561–1570. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh WK, Galsky MD, Stadler WM, Srinivas S,
Chu F, Bubley G, Goddard J, Dunbar J and Ross RW: Multicenter phase
II trial of the heat shock protein 90 inhibitor, retaspimycin
hydrochloride (IPI-504), in patients with castration-resistant
prostate cancer. Urology. 78:626–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Z, Jia L, Wang J, Wu X, Shi G, Lu C and
Shen Y: Discovery of novel 17-phenylethyla minegeldanamycin
derivatives as potent Hsp90 inhibitors. Chem Biol Drug Des.
85:181–188. 2015. View Article : Google Scholar
|
|
19
|
Wu Y, Li Z, Wang Z, Xu H, Wu X, Lu C and
Shen Y: Synthesis of novel 17-[3,6-Dioxa-8-N-(substituted
cinnamyol)- octanediamino]-17-demethoxygeldanamycin derivatives.
Chin J Org Chem. 34:1870–1874. 2014.In Chinese. View Article : Google Scholar
|
|
20
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mahdavinezhad A, Mousavi-Bahar SH,
Poorolajal J, Yadegarazari R, Jafari M, Shabab N and Saidijam M:
Evaluation of miR-141, miR-200c, miR-30b Expression and
Clinicopathological Features of Bladder Cancer. Int J Mol Cell Med.
4:32–39. 2015.PubMed/NCBI
|
|
22
|
Shen P, Sun J, Xu G, Zhang L, Yang Z, Xia
S, Wang Y, Liu Y and Shi G: KLF9, a transcription factor induced in
flutamide-caused cell apoptosis, inhibits AKT activation and
suppresses tumor growth of prostate cancer cells. Prostate.
74:946–958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baade PD, Youlden DR and Krnjacki LJ:
International epidemiology of prostate cancer: Geographical
distribution and secular trends. Mol Nutr Food Res. 53:171–184.
2009. View Article : Google Scholar
|
|
24
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huggins C and Hodges CV: Studies on
prostatic cancer. I. The effect of castration, of estrogen and
androgen injection on serum phosphatases in metastatic carcinoma of
the prostate. CA Cancer J Clin. 22:232–240. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Asmane I, Céraline J, Duclos B, Rob L,
Litique V, Barthélémy P, Bergerat JP, Dufour P and Kurtz JE: New
strategies for medical management of castration-resistant prostate
cancer. Oncology. 80:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lassi K and Dawson NA: Update on
castrate-resistant prostate cancer: 2010. Curr Opin Oncol.
22:263–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Corcoran NM and Gleave ME: Targeted
therapy in prostate cancer. Histopathology. 60:216–231. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pearl LH and Prodromou C: Structure and
mechanism of the Hsp90 molecular chaperone machinery. Annu Rev
Biochem. 75:271–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takayama S, Reed JC and Homma S:
Heat-shock proteins as regulators of apoptosis. Oncogene.
22:9041–9047. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lamoureux F, Thomas C, Yin MJ, Kuruma H,
Fazli L, Gleave ME and Zoubeidi A: A novel HSP90 inhibitor delays
castrate-resistant prostate cancer without altering serum PSA
levels and inhibits osteoclastogenesis. Clin Cancer Res.
17:2301–2313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saporita AJ, Ai J and Wang Z: The Hsp90
inhibitor, 17-AAG, prevents the ligand-independent nuclear
localization of androgen receptor in refractory prostate cancer
cells. Prostate. 67:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cano LQ, Lavery DN and Bevan CL:
Mini-review: Foldosome regulation of androgen receptor action in
prostate cancer. Mol Cell Endocrinol. 369:52–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang CK, Luo J, Lee SO and Chang C:
Concise review: Androgen receptor differential roles in
stem/progenitor cells including prostate, embryonic, stromal, and
hematopoietic lineages. Stem Cells. 32:2299–2308. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Johnson VA, Singh EK, Nazarova LA,
Alexander LD and McAlpine SR: Macrocyclic inhibitors of hsp90. Curr
Top Med Chem. 10:1380–1402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang H and Burrows F: Targeting multiple
signal transduction pathways through inhibition of Hsp90. J Mol Med
(Berl). 82:488–499. 2004. View Article : Google Scholar
|
|
39
|
Workman P, Burrows F, Neckers L and Rosen
N: Drugging the cancer chaperone HSP90: Combinatorial therapeutic
exploitation of oncogene addiction and tumor stress. Ann NY Acad
Sci. 1113:202–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pearl LH, Prodromou C and Workman P: The
Hsp90 molecular chaperone: An open and shut case for treatment.
Biochem J. 410:439–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Eskew JD, Sadikot T, Morales P, Duren A,
Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA,
et al: Development and characterization of a novel C-terminal
inhibitor of Hsp90 in androgen dependent and independent prostate
cancer cells. BMC Cancer. 11:4682011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Centenera MM, Fitzpatrick AK, Tilley WD
and Butler LM: Hsp90: Still a viable target in prostate cancer.
Biochim Biophys Acta. 1835:211–218. 2013.PubMed/NCBI
|
|
43
|
Porter JR, Fritz CC and Depew KM:
Discovery and development of Hsp90 inhibitors: A promising pathway
for cancer therapy. Curr Opin Chem Biol. 14:412–420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Soga S, Akinaga S and Shiotsu Y: Hsp90
inhibitors as anti-cancer agents, from basic discoveries to
clinical development. Curr Pharm Des. 19:366–376. 2013. View Article : Google Scholar
|
|
45
|
Price JT, Quinn JM, Sims NA, Vieusseux J,
Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie
MT and Thompson EW: The heat shock protein 90 inhibitor,
17-allylamino-17-demethoxygeldanamycin, enhances osteoclast
formation and potentiates bone metastasis of a human breast cancer
cell line. Cancer Res. 65:4929–4938. 2005. View Article : Google Scholar : PubMed/NCBI
|
